Watchman Group’s Accelerate Diagnostics AXDX Stock Holding History

Watchman Group’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,000	Closed	-$20K	–	69
2022 Q2	$20K	Hold	2,000	–	–	0.01%	68
2022 Q1	$28K	Buy	+2,000	New	+$57K	0.02%	73

Other funds holding AXDX

GAM

Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $214M AUM 45.87% 1-Year Est. Return

Watchman Group's AXDX Position: Q3 2022 in Review

Watchman Group sold out of Accelerate Diagnostics (AXDX) in Q3 2022, closing a stake of 2,000 shares — an estimated $20K sold.

Watchman Group first reported a position in AXDX in Q1 2022 and held it in 2 quarters. The position peaked at $28K in Q1 2022. 84 funds tracked by Wall St. Rank hold AXDX as of Q3 2022.

Watchman Group reported no remaining Accelerate Diagnostics position as of Q3 2022 after selling out during the quarter.
Watchman Group sold 2,000 Accelerate Diagnostics shares in Q3 2022, an estimated $20K.
Watchman Group first reported a position in Accelerate Diagnostics in Q1 2022 and held it in 2 quarters.
Watchman Group's Accelerate Diagnostics position peaked at $28K in Q1 2022.
84 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2022.

Based on Watchman Group's 13F filing for Q3 2022, filed 15 Nov 2022.